However, no differences in tumor growth and survival were seen between mice receiving [177Lu]Lu-PSMA-I&T/vehicle or receiving [177Lu]Lu-PSMA-I&T/veliparib or [177Lu]Lu-PSMA-I&T/olaparib when PARPi daily oral dosing was initiated simultaneously with PSMA-TRT. Here, FOLH1 is linked to neoplasm.